Re:Cognition Health is changing the future for those with memory loss and other symptoms of cognitive impairment, through providing education, clinical excellence and access to the most advanced treatments available worldwide.
It is an exciting time for research into Alzheimer’s disease and other causes of mild cognitive impairment (MCI) and dementia. Results from clinical trials are always encouraging, bringing us ever closer to treatments to slow or, ideally, halt the progression of the disease and to improve its symptoms.
Involvement in clinical trials enables individuals to receive the next generation of emerging medications, free of charge, before these medications are licensed for global use. Participants receive outstanding medical care and are monitored regularly throughout the study by a team of cognitive experts. All medical costs are covered by the pharmaceutical company.
Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by dementia and cognitive impairment. By participating in a research study, a person can make a direct impact on our ability to treat a given condition for society as a whole, whilst also gaining the potential benefit of early access to new treatments themselves.
Dr Emer MacSweeney, CEO and Medical Director of Re:Cognition Health comments: “With the introduction of new biomarkers to detect evidence of Alzheimer’s disease at its earliest stage, there is reason for cautious optimism that new generation medications will delay progression of disease and or boost cognition. ”
Re:Cognition Health is proud of the pioneering work being undertaken by the consultants and cognitive experts at the clinic and continues to work hard to become one of the most successful clinics in the world for enrolling individuals on to final phase international clinical trials for Alzheimer’s Disease.
Additional studies that are currently being carried out at Re:Cognition Health include:
The Amaranth and Daybreak studies, both sponsored by Eli Lilly, which are investigating the same BACE-inhibitor compound, LY3314814 in patients with mild cognitive impairment or Alzheimer’s disease. Re:Cognition Health is also currently offering patients who are asymptomatic, but at risk of developing Alzheimer’s disease, the opportunity to participate in a BACE-inhibitor study, sponsored by Janssen, should they be demonstrated to have positive biomarkers and therefore be be at increased risk of developing cognitive symptoms.
Other potential disease modifying treatments for mild cognitive impairment or Alzheimer’s disease being investigated by Re:Cognition Health include the adcucanumab in the Engage study, sponsored by Biogen, and the Steadfast study, sponsored by vTv Therapeutics. Re:Cognition Health will also be enrolling for a study investigating a potential new treatment for insomnia in patients who are also suffering from Alzheimer’s disease.
Alongside their work in the Alzheimer’s space, Re:Cognition Health is running studies for patients with migraine, sponsored by CoLucid and Lewy body dementia, sponsored by Axovant.
Peter Brabner, whose wife Helen was diagnosed with Alzheimer’s disease at the age of 73, is supporting her through the clinical study and is delighted to be part of potential future-changing research. He comments: “If someone has a diagnosis of Alzheimer’s Disease I would say get in touch with Re:Cognition Health: they are doing excellent work and look after you so well throughout the process. We are realistic that we may not find a cure in Helen’s lifetime but we are hoping to help other people in some way. Also, by doing something positive and pro-active about it is good for us both.” Helen began a clinical trial with Re:Cognition Health in Guildford in December 2016.
Full case study of Helen and Peter is available upon request.
For further information on the clinic studies and to arrange interviews with Re:Cognition Health’s esteemed consultants, please contact:
Alina Wallace: / 07946 189672 / E: firstname.lastname@example.org
Christina Macdonald: / 07957 360242 / E: email@example.com
About Re:Cognition Health:
Re:Cognition Health was established in 2011 to provide a specialist service in the neurological
assessment and imaging of cognitive impairment, neurovascular diseases and traumatic brain injury, including the provision medico-legal expert opinion. The Re:Cognition Clinics in London, Essex, Surrey and Plymouth are also major centres for international trials of disease-modifying and new symptomatic drugs for Alzheimer’s disease and other neurological conditions.
This press release was distributed by ResponseSource Press Release Wire on behalf of Healthy Content in the following categories: Health, Medical & Pharmaceutical, for more information visit https://pressreleasewire.responsesource.com/about.